On January 4, 2023, the FDA announced that mifepristone will be available in pharmacies that comply with certain requirements. While prescriber certification, patient agreement forms and a new pharmacy certification process remain barriers, the FDA's announcement is a great step in expanding equitable access to medication abortion pills. Through legislative and legal efforts, CAFP has long advocated for greater access to mifepristone and other reproductive health care services and we are pleased the FDA has taken this important step in the right direction.
More information can be found on the FDA website
